NL294835A - - Google Patents

Info

Publication number
NL294835A
NL294835A NL294835DA NL294835A NL 294835 A NL294835 A NL 294835A NL 294835D A NL294835D A NL 294835DA NL 294835 A NL294835 A NL 294835A
Authority
NL
Netherlands
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of NL294835A publication Critical patent/NL294835A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20Milk; Whey; Colostrum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL294835D 1962-07-19 NL294835A (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR904533A FR2427M (fr) 1962-07-19 1962-07-19 Médicament bactériothérapique, en particulier pour le traitement d'affections gastro-intestinales.

Publications (1)

Publication Number Publication Date
NL294835A true NL294835A (OSRAM) 1900-01-01

Family

ID=8783563

Family Applications (1)

Application Number Title Priority Date Filing Date
NL294835D NL294835A (OSRAM) 1962-07-19

Country Status (4)

Country Link
US (1) US3320130A (OSRAM)
BE (1) BE634858A (OSRAM)
FR (1) FR2427M (OSRAM)
NL (1) NL294835A (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE369470B (OSRAM) * 1972-06-16 1974-09-02 Wenner Gren Med Labor Ab
US3953609A (en) * 1974-02-06 1976-04-27 Microlife Technics, Inc. Method for the growth restriction of undesirable digestive system bacteria in animals and the establishment of lactobacillus lactis NRRL B-5628
AU559550B2 (en) * 1981-03-09 1987-03-12 Cetus Corporation Vaccines
SE463598B (sv) * 1984-11-08 1990-12-17 Chemical Dynamics Sweden Ab Preparat, avsett att oeka vidhaeftningen av bakterier till mag-tarmkanalen hos maenniskor och djur, samt ett framstaellningsfoerfarande foer detta
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US5804179A (en) * 1985-12-31 1998-09-08 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
ATE165738T1 (de) * 1988-08-02 1998-05-15 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
DE4033996A1 (de) * 1990-10-25 1992-04-30 Karl Heinz Hoelzel Enzymatisches stoffwechselprodukt zur symbioselenkung und verfahren zu seiner herstellung
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection
US5840318A (en) * 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
IT1299070B1 (it) * 1998-04-10 2000-02-07 Proge Farm Srl Ceppi di lattobacilli capaci di inibire e/o avere azione microbicida nei confronti di microorganismi patogeni e metodo di induzione e
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
AR052472A1 (es) * 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
CA2607949C (en) * 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
KR102216603B1 (ko) 2010-08-04 2021-02-17 크레스토보 홀딩스 엘엘씨 분변 세균총 이식을 위한 조성물, 그의 제조 방법과 사용 방법, 및 그를 전달하기 위한 장치
CA2829385C (en) 2011-03-09 2021-07-13 Michael J. Sadowsky Compositions and methods for transplantation of colon microbiota
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US9675667B2 (en) * 2015-02-10 2017-06-13 Massachusetts Institute Of Technology Isolated mucins and different microorganisms, and methods of use
JP6692897B2 (ja) 2015-05-14 2020-05-13 クレストヴォ・ホールディングス・エルエルシー 便フローラを移植するための組成物、並びにそれを調製及び使用する方法、並びにそれを送達するためのデバイス
AU2016268158B2 (en) 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
CN105347511B (zh) * 2015-11-30 2018-02-27 威海地宝生物科技有限公司 一种水产养殖用复合微生物制剂及方法
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
CA3058818A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
KR20210065969A (ko) 2018-09-27 2021-06-04 핀치 테라퓨틱스 홀딩스 엘엘씨 간질 및 관련 장애를 치료하기 위한 조성물 및 방법
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2697663A (en) * 1952-04-19 1954-12-21 American Home Prod Infant feeding compositions
US2811450A (en) * 1952-06-17 1957-10-29 Tervalon Mij Voor Voedingsmidd Method of producing food-preparations

Also Published As

Publication number Publication date
US3320130A (en) 1967-05-16
FR2427M (fr) 1964-03-31
BE634858A (OSRAM) 1900-01-01

Similar Documents

Publication Publication Date Title
AT13735B (OSRAM)
AT2567B (OSRAM)
CH21878A (OSRAM)
AT14238B (OSRAM)
AT14149B (OSRAM)
AT13281B (OSRAM)
AT13288B (OSRAM)
AT13314B (OSRAM)
AT13445B (OSRAM)
AT13568B (OSRAM)
AT12273B (OSRAM)
AT13632B (OSRAM)
AT13673B (OSRAM)
AT13733B (OSRAM)
AT11618B (OSRAM)
AT12149B (OSRAM)
FR434391A (OSRAM)
AT12220B (OSRAM)
AT13914B (OSRAM)
AT14032B (OSRAM)
AT14095B (OSRAM)
AT2581B (OSRAM)
AT6813B (OSRAM)
AT2598B (OSRAM)
AT2595B (OSRAM)